A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

NCT05003037 ·Status: UNKNOWN ·Phase: PHASE2

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

NCT07117890 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

NCT05962021 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer

NCT03808701 ·Status: UNKNOWN ·Phase: PHASE1

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

NCT06786208 ·Status: NOT_YET_RECRUITING

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

NCT04028778 ·Status: UNKNOWN ·Phase: PHASE3

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

NCT06080776 ·Status: RECRUITING ·Phase: PHASE3

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

NCT06634667 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

NCT06355609 ·Status: RECRUITING ·Phase: PHASE2

A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC

NCT03823807 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

NCT03849768 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

NCT03457337 ·Status: UNKNOWN ·Phase: PHASE2

The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy

NCT04667975 ·Status: UNKNOWN ·Phase: PHASE1

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

NCT05435274 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC

NCT06690671 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen

NCT01850147 ·Status: UNKNOWN ·Phase: PHASE2

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

NCT06348927 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer

NCT02535507 ·Status: UNKNOWN ·Phase: PHASE2

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

NCT03607188 ·Status: COMPLETED ·Phase: PHASE1

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

NCT06623136 ·Status: RECRUITING ·Phase: PHASE2

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

NCT05394831 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

NCT06685718 ·Status: TERMINATED ·Phase: PHASE1